Breaking News

Tweet TWEET

Decision Resources to Publish Reports Assessing Unmet Need and Commercial Opportunities in the Cardiovascular and Metabolic

  Decision Resources to Publish Reports Assessing Unmet Need and Commercial
   Opportunities in the Cardiovascular and Metabolic Diseases Drug Markets

PR Newswire

BURLINGTON, Mass., Dec. 17, 2013

BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, will soon publish analysis of unmet need and commercial
opportunities for developers of drugs that treat cardiovascular and metabolic
diseases.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Some of the key findings in these reports include the following:

  oSurveyed U.S. and European primary care physicians agree that increased
    weight-loss efficacy is one of the attributes that most influences their
    decisions regarding prescribing in obesity. Clinical data and the opinions
    of interviewed thought leaders indicate that phentermine (UCB's Ionamin,
    generics), Vivus's Qsymia, Orexigen/Takeda's Contrave, Novo Nordisk's
    Victoza and Zafgen's beloranib have advantages on this attribute over
    sales-leading orlistat (Roche's Xenical, generics; GlaxoSmithKline's
    Alli).
  oSurveyed U.S. and European pulmonologists agree that improved long-term
    survival is one of the attributes that most influences their decisions
    regarding prescribing in pulmonary arterial hypertension. Clinical data
    and the opinions of interviewed thought leaders indicate that
    Actelion/Nippon Shinyaku's Opsumit has advantages on this attribute over
    sales-leading Actelion's Tracleer.
  oThe availability of generic metformin and sulfonylureas for the treatment
    of type 2 diabetes will continue to have a substantial influence on
    physicians' prescribing and payers' formulary coverage. The struggles of
    managed care organizations (MCOs) to contain healthcare costs often lead
    them to encourage use of generics in early lines of therapy. New classes
    of antidiabetic agents face considerable reimbursement hurdles,
    particularly if they are expensive. Emerging therapies that are
    reformulations of already-available molecules, with limited advantages
    beyond delivery, will likely face significant market access hurdles and
    stiff MCO resistance to formulary inclusion, if priced at a premium to
    their parent molecules.

These findings can be found in the following reports which will publish in the
days ahead:

  oObesity: What Key Attributes Will Drive Formulary Inclusion and
    Prescribing of Current and Emerging Agents?
  oWhat Key Attributes Will Drive Pulmonologists to Prescribe and Payers to
    Reimburse Novel PAH Agents?
  oNovel SGLT-2 Inhibitors, Next-Generation Once-Weekly GLP-1 Receptor
    Agonists, and New Insulins Appear on the Horizon for Type 2 Diabetes: What
    Market Access Challenges Will These New Therapies Face?

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or
registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://www.decisionresources.com
Contact: Decision Resources Group: Christopher Comfort, 781-993-2597,
ccomfort@dresources.com
 
Press spacebar to pause and continue. Press esc to stop.